Literature DB >> 24570912

Targeted agents: how can we improve the outcome in biliary tract cancer?

Donatella Marino1, Federica Colombi1, Dario Ribero2, Massimo Aglietta1, Francesco Leone1.   

Abstract

Entities:  

Year:  2013        PMID： 24570912      PMCID： PMC3924636          DOI： 10.3978/j.issn.2304-3881.2012.09.03

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

1.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Phase II study of erlotinib in patients with advanced biliary cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Authors:  Jeeyun Lee; Se Hoon Park; Heung-Moon Chang; Jun Suk Kim; Hye Jin Choi; Myung Ah Lee; Joung Soon Jang; Joung Soon Chang; Hei Cheul Jeung; Jung Hun Kang; Hyun Woo Lee; Dong Bok Shin; Hye Jin Kang; Jong-Mu Sun; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim
Journal:  Lancet Oncol       Date:  2011-12-20       Impact factor: 41.316

6.  Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Authors:  Giuliana Cavalloni; Caterina Peraldo-Neia; Ivana Sarotto; Loretta Gammaitoni; Giorgia Migliardi; Marco Soster; Serena Marchiò; Massimo Aglietta; Francesco Leone
Journal:  Mol Cancer Ther       Date:  2012-03-27       Impact factor: 6.261

7.  Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

Authors:  Atul Sharma; Amit Dutt Dwary; Bidhu Kalyan Mohanti; Surya V Deo; Sujoy Pal; Vishnu Sreenivas; Vinod Raina; Nootan Kumar Shukla; Sanjay Thulkar; Pramod Garg; Surendra Pal Chaudhary
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

8.  Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

Authors:  Francesco Leone; Giuliana Cavalloni; Ymera Pignochino; Ivana Sarotto; Renato Ferraris; Wanda Piacibello; Tiziana Venesio; Lorenzo Capussotti; Mauro Risio; Massimo Aglietta
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

9.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Authors:  Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

10.  Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.

Authors:  Lisa Y Law
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  3 in total

1.  A novel PTEN gene promoter mutation and untypical Cowden syndrome.

Authors:  Chen Liu; Guangbing Li; Rongrong Chen; Xiaobo Yang; Xue Zhao; Haitao Zhao
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

2.  Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.

Authors:  Jianzhen Lin; Xu Yang; Junyu Long; Songhui Zhao; Jinzhu Mao; Dongxu Wang; Yi Bai; Jin Bian; Lei Zhang; Xiaobo Yang; Anqiang Wang; Fucun Xie; Weiwei Shi; Huayu Yang; Jie Pan; Ke Hu; Mei Guan; Lin Zhao; Li Huo; Yilei Mao; Xinting Sang; Kai Wang; Haitao Zhao
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

3.  Surgical procedure determination based on tumor-node-metastasis staging of gallbladder cancer.

Authors:  Xiao-Dong He; Jing-Jing Li; Wei Liu; Qiang Qu; Tao Hong; Xie-Qun Xu; Bing-Lu Li; Ying Wang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.